Pre-procedural SGLT2 inhibitors use significantly reduces CIN incidence, mortality, MACE, and HF readmission in PCI-treated AMI patients, suggesting potential cardiorenal protective benefits. This evidence concerns the gene SLC5A2 and hydrops fetalis.